Tectonic completes patient recruitment for study on heart failure drug (opens in new tab)

Tectonic has completed enrollment in the APEX 24-week Phase 2 trial evaluating TX45 in patients with pulmonary hypertension associated with heart failure with preserved ejection fraction (PH-HFpEF), according to the company. The randomized, double-blind, placebo-controlled study enrolled 191 patients across 14 countries and was designed to enrich for the combined pre- and post-capillary pulmonary hypertension […] The post appeared first on <a href="